| Autor: |
Timmermans, Sjoerd A.M.E.G., Abdul-Hamid, Myrurgia A., Vanderlocht, Joris, Damoiseaux, Jan G.M.C., Reutelingsperger, Chris P., van Paassen, Pieter, de Heer, F., Krekels, M., Stifft, F., Verseput, G., Boorsma, S., Grave, W., Huitema, J., Wirtz, J., ter Braak, N., Frenken, L., Gaertner, S., Christiaans, M., Fung, T., Gelens, M., Kooman, J., Leunissen, K., Litjens, E., van der Net, J., van der Sande, F., van Duijnhoven, E. |
| Zdroj: |
Kidney International; June 2017, Vol. 91 Issue: 6 p1420-1425, 6p |
| Abstrakt: |
Thrombotic microangiopathy (TMA) is a pattern of endothelial damage that can be found in association with diverse clinical conditions such as malignant hypertension. Although the pathophysiological mechanisms differ, accumulating evidence links complement dysregulation to various TMA syndromes and in particular the atypical hemolytic uremic syndrome. Here, we evaluated the role of complement in nine consecutive patients with biopsy-proven renal TMA attributed to severe hypertension. Profound hematologic symptoms of TMA were uncommon. In six out of nine patients, we found mutations C3in three, CFIin one, CD46in one, and/or CFHin two patients either with or without the risk CFH-H3 haplotype in four patients. Elevated levels of the soluble C5b-9 and renal deposits of C3c and C5b-9 along the vasculature and/or glomerular capillary wall, confirmed complement activation in vivo. In contrast to patients without genetic defects, patients with complement defects invariably progressed to end-stage renal disease, and disease recurrence after kidney transplantation seems common. Thus, a subset of patients with hypertension-associated TMA falls within the spectrum of complement-mediated TMA, the prognosis of which is poor. Hence, testing for genetic complement abnormalities is warranted in patients with severe hypertension and TMA on renal biopsy to adopt suitable treatment options and prophylactic measures. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
